Login

Categories

Careers Consumer Corporate Energy Entertainment Experts Financials Healthcare Industrial Law Markets Media Mining Private Equity Real Estates Sports Startups Technology Venture Capital

Recent Videos

00:00:00
Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020 - Gary J Phillips B Pharm MBA - Chief Executive Officer, Pharmaxis Ltd
00:00:00
Pharmaxis welcomes positive interim data for Phase 2 cancer trial - Gary J Phillips B Pharm MBA - Chief Executive Officer, Pharmaxis Ltd
00:00:00
Pharmaxis extends scarring collaboration after encouraging results - Gary J Phillips B Pharm MBA - Chief Executive Officer, Pharmaxis Ltd
00:00:00
Orthocell raising $3.5 million; adds heavy hitters to register - Mr Paul Anderson Chief Executive Officer and Managing Director, Orthocell Ltd
00:10:00
Ionic Rare Earths (ASX: IXR) Unveils Two-Pronged Strategy to Disrupt Global Rare Earths Market: European Recycling and African Production Set to Break China's Stranglehold|Tim Harrison, the managing director of Ionic Rare Earths
00:10:00
Streamlining Geological Field Mapping with ArcGIS Pro & Discover Mobile | Sarah Smith , CEO of Datamine Software Canada
00:10:00
Reducing Audit Costs: Insights from Erez Bahar | EREZ BAHAR, Managing Partner at Davidson & Company LLP
00:10:00
Unlocking Earth's Secrets from Above: The Science of Airborne Geophysics | Dayk Mühendislik , Founder of DAYK GROUP
00:10:00
Ionic Rare Earths is focused on developing its flagship Makuutu Rare Earths Project in Uganda into a significant long life, low-cost, supplier of high-value critical and heavy rare earths|Tim Harrison, Managing Director of Ionic Rare Earths (ASX:IXR)
00:00:00
NetScientific PLC discusses FDA fast-track of its portfolio company's cancer treatment - Dr. Ilian Iliev CHIEF EXECUTIVE OFFICER, Netscientific
00:00:00
ASX Small & Mid Cap Conference: Neuren Pharmaceuticals Limited - Jon Pilcher, BSc (Hons), FCA Chief Executive Officer/Managing Director, Neuren Pharmaceuticals Ltd
00:00:00
Biotech Unlocked - NEUREN PHARMACEUTICALS - ASX:NEU - Jon Pilcher, BSc (Hons), FCA Chief Executive Officer/Managing Director, Neuren Pharmaceuticals Ltd
00:00:00
Neuren Pharmaceuticals CEO Jon Pilcher discusses on Phase 3 LAVENDER Rett Syndrome trial. - Jon Pilcher, BSc (Hons), FCA Chief Executive Officer/Managing Director, Neuren Pharmaceuticals Ltd
00:00:00
Erik Kinnman, CEO, NeuroVive Pharmaceutical
00:00:00
Catherine Turkel Discusses Pharmacy School and Novus Therapeutics - Catherine Turkel, President, Novus Therapeutics Inc
00:00:00
Noxopharm CEO talks Veyonda orphan drug designation from US FDA - Dr Gisela Mautner Chief Executive Officer and Managing Director, Noxopharm Ltd
00:00:00
Noxopharm details science-driven strategy in new investor presentation - Dr Gisela Mautner Chief Executive Officer and Managing Director, Noxopharm Ltd
00:00:00
Noxopharm hails new Sofra™ drug inflammation results - Dr Gisela Mautner Chief Executive Officer and Managing Director, Noxopharm Ltd
00:00:00
Noxxon CEO discusses partners and cancer combinations - Aram Mangasarian , CEO, NOXXON Pharma
00:00:00
Aram Mangasarian , CEO, NOXXON Pharma

© 2017 - Eemu.live